var data={"title":"Aldesleukin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aldesleukin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5581?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aldesleukin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aldesleukin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=aldesleukin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aldesleukin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708605\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiopulmonary disease: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Restrict therapy with aldesleukin to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Use extreme caution in patients with a normal thallium stress test and a normal pulmonary function test who have a history of cardiac or pulmonary disease.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Administer aldesleukin in a hospital setting under the supervision of a qualified physician experienced in the use of anticancer agents. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">CNS toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Withhold aldesleukin administration in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Capillary leak syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Aldesleukin administration has been associated with capillary leak syndrome (CLS) which is characterized by a loss of vascular tone and extravasation of plasma proteins and fluid into the extravascular space. CLS results in hypotension and reduced organ perfusion which may be severe and can result in death. CLS may be associated with cardiac arrhythmias (supraventricular and ventricular), angina, myocardial infarction, respiratory insufficiency requiring intubation, gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental status changes.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Aldesleukin treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of aldesleukin therapy. Patients with indwelling central lines are particularly at risk for infection with gram-positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin, or vancomycin has been associated with a reduced incidence of staphylococcal infections.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12806506\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Proleukin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131251\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Proleukin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131288\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Biological Response Modulator;</li>\n      <li>\n        Antineoplastic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131255\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Consider premedication with an antipyretic to reduce fever, an H<sub>2</sub> antagonist for prophylaxis of gastrointestinal irritation/bleeding, antiemetics, and antidiarrheals; continue for 12 hours after the last aldesleukin dose. Antibiotic prophylaxis is recommended to reduce the incidence of infection. Aldesleukin doses &gt;12 to 15 million units/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Renal cell carcinoma, metastatic:</b> IV: 600,000 units/kg every 8 hours for a maximum of 14 doses; repeat after 9 days for a total of 28 doses per course; re-treat if tumor shrinkage observed (and if no contraindications) at least 7 weeks after hospital discharge date</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Off-label dosing: 720,000 units/kg every 8 hours for up to 12 doses; repeat with a second cycle 10 to 15 days later (Klapper, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Melanoma, metastatic:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Single-agent use:</i> 600,000 units/kg every 8 hours for a maximum of 14 doses; repeat after 9 days for a total of 28 doses per course; re-treat if tumor shrinkage observed (and if no contraindications) at least 7 weeks after hospital discharge date</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Off-label dosing: 720,000 units/kg every 8 hours for 12 to 15 doses; repeat with a second cycle ~14 days after the first dose of the initial cycle (Smith, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Combination biochemotherapy (off-label use):</i> 9 million units/m<sup>2</sup>/day continuous infusion over 24 hours for 4 days every 3 weeks for up to 4 cycles (Atkins, 2008) <b>or</b> 9 million units/m<sup>2</sup>/day continuous infusion over 24 hours days 5 to 8, 17 to 20, and 26 to 29 every 42 days for up to 5 cycles (Eton, 2002) <b>or</b> 9 million units/m<sup>2</sup>/day continuous infusion over 24 hours for 4 days every 3 weeks for 6 cycles (Legha, 1998)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647544\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=aldesleukin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aldesleukin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Consider premedication with an antipyretic to reduce fever, an H<sub>2</sub> antagonist for prophylaxis of gastrointestinal irritation/bleeding, antiemetics, and antidiarrheals; continue for 12 hours after the last aldesleukin dose. Antibiotic prophylaxis is recommended to reduce the incidence of infection. Aldesleukin doses &gt;12 to 15 million units/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Neuroblastoma (off-label use):</b> IV: 3 million units/m<sup>2</sup>/day continuous infusion over 24 hours daily for 4 days during week 1 and 4.5 million units/m<sup>2</sup>/day continuous infusion over 24 hours daily for 4 days during week 2 of cycles 2 and 4 (regimen also includes isotretinoin, dinutuximab, and sargramostim) (Yu, 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131256\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2620612\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Renal impairment prior to treatment initiation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum creatinine &le;1.5 mg/dL: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum creatinine &gt;1.5 mg/dL: Do not initiate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Renal toxicity during treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum creatinine &gt;4.5 mg/dL (or &ge;4 mg/dL with severe volume overload, acidosis, or hyperkalemia): Withhold dose; may resume when &lt;4 mg/dL and fluid/electrolyte status is stable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent oliguria or urine output &lt;10 mL/hour for 16 to 24 hours with rising serum creatinine: Withhold dose; may resume when urine output &gt;10 mL/hour with serum creatinine decrease of &gt;1.5 mg/dL or normalization.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Re-treatment is contraindicated in patients with renal failure requiring dialysis for &gt;72 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26620521\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment prior to treatment initiation: </i>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity during treatment:</i> Signs of hepatic failure (encephalopathy, increasing ascites, liver pain, hypoglycemia): Withhold dose and discontinue treatment for balance of cycle; may initiate a new course if indicated only after at least 7 weeks past resolution of all signs of hepatic failure (including hospital discharge). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647545\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Withhold or interrupt a dose for toxicity; do not reduce the dose.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Cardiovascular toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Atrial fibrillation, supraventricular tachycardia, or bradycardia that is persistent, recurrent, or requires treatment: Withhold dose; may resume when asymptomatic with full recovery to normal sinus rhythm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Systolic BP &lt;90 mm Hg (with increasing pressor requirements): Withhold dose; may resume treatment when systolic BP &ge;90 mm Hg and stable or pressor requirements improve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Any ECG change consistent with MI, ischemia or myocarditis (with or without chest pain), or suspected cardiac ischemia: Withhold dose; may resume when asymptomatic, MI/myocarditis have been ruled out, suspicion of angina is low, or there is no evidence of ventricular hypokinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>CNS toxicity:</i> Mental status change, including moderate confusion or agitation: Withhold dose; may resume when resolved completely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Dermatologic toxicity:</i> Bullous dermatitis or marked worsening of preexisting skin condition: Withhold dose; may treat with antihistamines or topical products (do not use topical steroids); may resume with resolution of all signs of bullous dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Gastrointestinal:</i> Stool guaiac repeatedly &gt;3-4+: Withhold dose; may resume with negative stool guaiac.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Infection:</i> Sepsis syndrome, clinically unstable: Withhold dose; may resume when sepsis syndrome has resolved, patient is clinically stable, and infection is under treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Respiratory toxicity:</i> Oxygen saturation &lt;90%: Withhold dose; may resume when &gt;90%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Re-treatment with aldesleukin is contraindicated with the following toxicities:</i></b> Sustained ventricular tachycardia (&ge;5 beats), uncontrolled or unresponsive cardiac arrhythmias, chest pain with ECG changes consistent with angina or MI, cardiac tamponade, intubation &gt;72 hours, renal failure requiring dialysis for &gt;72 hours, coma or toxic psychosis lasting &gt;48 hours, repetitive or refractory seizures, bowel ischemia/perforation, or GI bleeding requiring surgery</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131230\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proleukin: 22,000,000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131215\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131233\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Aldesleukin doses &gt;12 to 15 million units/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis, 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer as IV infusion over 15 minutes (do not administer with an inline filter). Allow solution to reach room temperature prior to administration. Flush before and after with D<sub>5</sub>W, particularly if maintenance IV line contains sodium chloride. Some off-label uses/doses are infused as a continuous infusion (Legha, 1998; Yu, 2010). Has also been administered by SubQ injection (off-label route).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131231\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma, metastatic:</b> Treatment of metastatic melanoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell cancer, metastatic:</b> Treatment of metastatic renal cell cancer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Careful patient selection is necessary. Assess performance status (PS); patients with a more favorable PS (Eastern Cooperative Oncology Group [ECOG] PS 0) at treatment initiation respond better to aldesleukin (higher response rate and lower toxicity). Experience in patients with ECOG PS &gt;1 is limited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26620648\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Neuroblastoma, high-risk (pediatrics)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131296\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aldesleukin may be confused with oprelvekin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proleukin may be confused with oprelvekin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131222\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypotension (71%, grade 4: 3%), peripheral edema (28%), tachycardia (23%), edema (15%), vasodilatation (13%), supraventricular tachycardia (12%, grade 4: 1%), cardiac disease (11%; includes blood pressure changes, HF and ECG changes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Chills (52%), confusion (34%, grade 4: 1%), malaise (27%), drowsiness (22%), anxiety (12%), pain (12%), dizziness (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (42%), pruritus (24%), exfoliative dermatitis (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Weight gain (16%), acidosis (12%, grade 4: 1%), hypomagnesemia (12%), hypocalcemia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (67%, grade 4: 2%), vomiting (19% to 50%, grade 4: 1%), nausea (19% to 35%), stomatitis (22%), anorexia (20%), abdominal pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Oliguria (63%, grade 4: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Thrombocytopenia (37%, grade 4: 1%), anemia (29%), leukopenia (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hyperbilirubinemia (40%, grade 4: 2%), increased serum AST (23%, grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immunologic: Antibody development (66% to 74%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (13%, grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (29%, grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine (33%, grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea (43%, grade 4: 1%), pulmonary disease (24%; includes pulmonary congestion, rales, rhonchi), cough (11%), respiratory tract disease (11%; includes acute respiratory distress syndrome, pulmonary infiltrates, and pulmonary changes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Cardiac arrhythmia (10%), cardiac arrest (grade 4: 1%), myocardial infarction (grade 4: 1%), ventricular tachycardia (grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Coma (grade 4: 2%), psychosis (grade 4: 1%), stupor (grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Enlargement of abdomen (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Anuria (grade 4: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Blood coagulation disorder (grade 4: 1%; includes intravascular coagulopathy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Sepsis (grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Acute renal failure (grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Rhinitis (10%), apnea (grade 4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Agitation, allergic interstitial nephritis, anaphylaxis, angioedema, asthma, atrial arrhythmia, atrioventricular block, blindness (transient or permanent), bowel infarction, bradycardia, brain disease, bullous pemphigoid, capillary leak syndrome, cardiomyopathy, cellulitis, cerebral edema, cerebral lesion, cerebral vasculitis, cerebrovascular accident, cholecystitis, colitis, delirium, depression (severe; leading to suicide), diabetes mellitus, duodenal ulcer, endocarditis, eosinophilia, exacerbation of Crohn's disease, extrapyramidal reaction, gastritis, hematemesis, hemoptysis, hemorrhage (including cerebral, gastrointestinal, retroperitoneal, subarachnoid, subdural), hepatic failure, hepatitis, hepatosplenomegaly, hypertension, hyperthyroidism, hyperuricemia, hyperventilation, hypothermia, hypoventilation, hypoxia, IgA glomerulonephritis (crescentic), increased blood urea nitrogen, increased nonprotein nitrogen, inflammatory arthritis, insomnia, intestinal necrosis, intestinal obstruction, intestinal perforation, ischemic heart disease, leukocytosis, lymphocytopenia, malignant hyperthermia, meningitis, myasthenia gravis (oculo-bulbar), mydriasis, myocarditis, myopathy, myositis, neuralgia, neuritis, neuropathy, neutropenia, optic neuritis, pancreatitis, paranoia, pericardial effusion, pericarditis, peripheral gangrene, phlebitis, pneumonia, pneumothorax, pulmonary edema, pulmonary embolism, renal tubular necrosis, respiratory acidosis, respiratory arrest, respiratory failure, restricted systemic blood flow, rhabdomyolysis, scleroderma, seizure, shock, Stevens-Johnson syndrome, syncope, thrombosis, thyroiditis, tissue necrosis at injection site, tracheoesophageal fistula, transient ischemic attacks, urticaria, ventricular premature contractions </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131236\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to aldesleukin or any component of the formulation; patients with abnormal thallium stress or pulmonary function tests; patients who have had an organ allograft. <b>Re-treatment is contraindicated</b> in patients who have experienced sustained ventricular tachycardia (&ge;5 beats), uncontrolled or unresponsive  cardiac arrhythmias, chest pain with ECG changes consistent with angina or MI, cardiac tamponade, intubation &gt;72 hours, renal failure requiring dialysis for &gt;72 hours, coma or toxic psychosis lasting &gt;48 hours, repetitive or refractory seizures, bowel ischemia/perforation, or GI bleeding requiring surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131219\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adverse effects: Are frequent and sometimes fatal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Capillary leak syndrome: <b>[US Boxed Warning]: Aldesleukin therapy is associated with capillary leak syndrome (CLS), characterized by vascular tone loss and extravasation of plasma proteins and fluid into extravascular space. CLS results in hypotension and reduced organ perfusion, which may be severe and can result in death. Cardiac arrhythmia, angina, myocardial infarction, respiratory insufficiency (requiring intubation), gastrointestinal bleeding or infarction, renal insufficiency, edema and mental status changes are also associated with CLS.</b> CLS onset is immediately after treatment initiation. Monitor fluid status and organ perfusion status carefully; consider fluids and/or pressor agents to maintain organ perfusion. Withhold treatment for signs of organ hypoperfusion, including altered mental status, reduced urine output, systolic BP &lt;90 mm Hg or cardiac arrhythmia. Once blood pressure is normalized, may consider diuretics for excessive weight gain/edema. Recovery from CLS generally begins soon after treatment cessation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS toxicity: <b>[US Boxed Warning]: Withhold treatment for patients developing moderate-to-severe lethargy or somnolence; continued treatment may result in coma.</b> Mental status changes (irritability, confusion, depression) can occur and may indicate bacteremia, sepsis, hypoperfusion, CNS malignancy, or CNS toxicity. May cause seizure; use with caution in patients with seizure disorder. Ethanol use may increase CNS adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Aldesleukin doses &gt;12 to 15 million units/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b> [US Boxed Warning]: Impaired neutrophil function is associated with treatment; patients are at risk for disseminated infection (including sepsis and bacterial endocarditis), and central line-related gram-positive infections. Treat preexisting bacterial infection appropriately prior to treatment initiation. Antibiotic prophylaxis that has been associated with a reduced incidence of staphylococcal infections in aldesleukin studies includes the use of oxacillin, nafcillin, ciprofloxacin, or vancomycin.</b> Monitor for signs of infection or sepsis during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Thyroid disease (hypothyroidism, biphasic thyroiditis, and thyrotoxicosis) may occur; the onset of hypothyroidism is usually 4 to 17 weeks after treatment initiation; may be reversible upon treatment discontinuation (Hamnvik, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune/inflammatory disorders: Use with caution in patients with autoimmune disease or inflammatory disorders; exacerbation and/or new onset have been reported with aldesleukin and interferon alfa combination therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiopulmonary disease: <b>[US Boxed Warning]: Treatment with aldesleukin should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress and formal pulmonary function testing. Extreme caution should be used in patients with a history of prior cardiac or pulmonary disease</b> and in patients who are fluid-restricted or where edema may be poorly tolerated. In a scientific statement from the American Heart Association, interleukin-2 has been determined to be an agent that may either cause direct myocardial toxicity (rare) or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS metastases: Patients should be evaluated and treated for CNS metastases and have a negative scan prior to treatment. New neurologic symptoms and lesions have been reported in patients without preexisting evidence of CNS metastases; symptoms generally improve upon discontinuation, however, cases with permanent damage have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic function: May impair hepatic function; concomitant hepatotoxic agents may increase the risk of hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal function: Patients must have a serum creatinine &le;1.5 mg/dL prior to treatment. May impair renal function; concomitant nephrotoxic agents may increase the risk of renal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Supportive care for high-dose treatment: Standard prophylactic supportive care during high-dose aldesleukin treatment includes acetaminophen to relieve constitutional symptoms and an H<sub>2</sub> antagonist to reduce the risk of GI ulceration and/or bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: The incidence of dyspnea and severe urogenital toxicities is potentially increased in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transplant patients: Enhancement of cellular immune function may increase the risk of allograft rejection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate patient selection: Perform a thorough clinical evaluation prior to treatment initiation. Exclude patients with significant cardiac, pulmonary, renal, hepatic, or central nervous system impairment from treatment. Patients with a more favorable performance status prior to treatment initiation are more likely to respond to aldesleukin treatment, with a higher response rate and generally lower toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media: An acute array of symptoms resembling aldesleukin adverse reactions (fever, chills, nausea, rash, pruritus, diarrhea, hypotension, edema, and oliguria) were observed within 1-4 hours after iodinated contrast media administration, usually when given within 4 weeks after aldesleukin treatment, although  has been reported several months after aldesleukin treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician:<b> [US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician in a facility with cardiopulmonary or intensive specialists and intensive care facilities available.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298698\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131224\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9413&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids: May diminish the antineoplastic effect of Aldesleukin.<b> Exceptions: </b>Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Hydrocortisone (Ophthalmic); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interferons (Alfa): May enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iodinated Contrast Agents: Aldesleukin may enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131226\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131239\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Use during pregnancy only if benefits to the mother outweigh potential risk to the fetus. Effective contraception is recommended for fertile males and/or females using this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5520981\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if aldesleukin is excreted in breast milk. Due to the potential for serious adverse reactions in the breast-feeding infant, a decision should be made to discontinue breast-feeding or to discontinue the drug, taking into account the importance of treatment to the mother. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131228\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Baseline and periodic: CBC with differential and platelets, blood chemistries including electrolytes, renal and hepatic function tests, and chest x-ray; pulmonary function tests and arterial blood gases (baseline), thallium stress test (prior to treatment). Monitor thyroid function tests (TSH at baseline then every 2-3 months during aldesleukin treatment [Hamnvik, 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Monitoring during therapy should include daily (hourly if hypotensive) vital signs (temperature, pulse, blood pressure, and respiration rate), weight and fluid intake and output; in a patient with a decreased blood pressure, especially systolic BP &lt;90 mm Hg, cardiac monitoring for rhythm should be conducted. If an abnormal complex or rhythm is seen, an ECG should be performed; vital signs in these hypotension patients should be taken hourly and central venous pressure (CVP) checked; monitor for change in mental status, and for signs of infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131218\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Aldesleukin is a human recombinant interleukin-2 product which promotes proliferation, differentiation, and recruitment of T and B cells, natural killer (NK) cells, and thymocytes; causes cytolytic activity in a subset of lymphocytes and subsequent interactions between the immune system and malignant cells; can stimulate lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL) cells. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131235\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Not absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Primarily into plasma, lymphocytes, lungs, liver, kidney, and spleen; V<sub>d</sub>: 6.3 to 7.9 L (Whittington 1993) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Renal (metabolized to amino acids in the cells lining the proximal convoluted tubules of the kidney)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Distribution: 14 &plusmn; 6 minutes; Elimination: 51 &plusmn; 11 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Distribution: 13 minutes; Terminal: 85 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422186\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Proleukin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22000000 unit (1): $4,684.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038320\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Celeuk (JP);</li>\n      <li>Interleukina 2 (PY);</li>\n      <li>Interleukina II (CL);</li>\n      <li>Proleukin (AE, AR, AT, BB, BE, BR, CH, CO, DE, DK, EC, EG, ES, FI, FR, GB, GR, HK, HN, HU, IL, IS, IT, KR, LB, NL, NZ, PE, PL, PT, RU, SG, SI, TR, TW, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Atkins MB, Hsu J, Lee S, et al, &ldquo;Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group,&rdquo; <i>J Clin Oncol</i>, 2008, 26(35):5748-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/19001327/pubmed\" target=\"_blank\" id=\"19001327\">19001327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atkins MB, Lotze MT, Dutcher JP, et al, &ldquo;High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993,&rdquo; <i>J Clin Oncol</i>, 1999, 17(7):2105-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/10561265/pubmed\" target=\"_blank\" id=\"10561265\">10561265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eton O, Legha SS, Bedikian AY, et al, &ldquo;Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial,&rdquo;<i>J Clin Oncol</i>, 2002, 20(8):2045-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/11956264/pubmed\" target=\"_blank\" id=\"11956264\">11956264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. <i>J Natl Cancer Inst</i>. 2011;103(21):1572-1587.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klapper JA, Downey SG, Smith FO, et al, &ldquo;High-Dose Interleukin-2 for the Treatment of Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Response and Survival in Patients Treated in the Surgery Branch at the National Cancer Institute Between 1986 and 2006,&rdquo; <i>Cancer</i>, 2008, 113(2):293-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/18457330/pubmed\" target=\"_blank\" id=\"18457330\">18457330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legha SS, Ring S, Eton O, et al, &ldquo;Development of a Biochemotherapy Regimen With Concurrent Administration of Cisplatin, Vinblastine, Dacarbazine, Interferon Alfa, and Interleukin-2 for Patients With Metastatic Melanoma,&rdquo;<i>J Clin Onco</i>l, 1998, 16(5):1752-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/9586888/pubmed\" target=\"_blank\" id=\"9586888\">9586888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procopio G, Verzoni E, Bracarda S, et al; Italian Trials in Medical Oncology (ITMO) group. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Ann Oncol</i>. 2013;24(12):2967-2971.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/24063860/pubmed\" target=\"_blank\" id=\"24063860\">24063860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Proleukin (aldesleukin) [prescribing information]. SanDiego, California: Prometheus Laboraories Inc; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith FO, Downey SG, Klapper JA, et al, &ldquo;Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction With Vaccines,&rdquo; <i>Clin Cancer Res</i>, 2008, 14(17):5610-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/18765555/pubmed\" target=\"_blank\" id=\"18765555\">18765555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whittington R and Faulds D, &ldquo;Interleukin-2: A Review of Its Pharmacological Properties and Therapeutic Use in Patients With Cancer,&rdquo; <i>Drugs</i>, 1993, 46(3):446-514.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang JC, Sherry RM, Steinberg, SM, et al, &ldquo;Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer,&rdquo; <i>J Clin Oncol</i>, 2003, 21(16): 3127-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/12915604/pubmed\" target=\"_blank\" id=\"12915604\">12915604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20879881\"></a>Yu AL, Gilman AL, Ozkaynak MF, et al; Children&rsquo;s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. <i>N Engl J Med</i>. 2010;363(14):1324-1334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/20879881/pubmed\" target=\"_blank\" id=\"20879881\">20879881</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9413 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708605\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F12806506\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F131251\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F131288\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F131255\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9647544\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F131256\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2620612\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26620521\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F9647545\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F131230\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F131215\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F131233\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F131231\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F26620648\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F131296\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F131222\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F131236\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F131219\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298698\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F131224\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F131226\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F131239\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5520981\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F131228\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F131218\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F131235\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422186\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038320\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9413|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aldesleukin-patient-drug-information\" class=\"drug drug_patient\">Aldesleukin: Patient drug information</a></li><li><a href=\"topic.htm?path=aldesleukin-pediatric-drug-information\" class=\"drug drug_pediatric\">Aldesleukin: Pediatric drug information</a></li></ul></div></div>","javascript":null}